Purchase Order 75H71026P00002
- Not listed
- The Indian Health Service awarded a purchase order to Cepheid Inc., a molecular diagnostic solutions manufacturer based in Sunnyvale, California, on October 16, 2025. The contract, valued at $260,025, runs from October 19, 2025, through October 18, 2026, with an ultimate completion date of October 18, 2030. Utilizing firm fixed-price pricing with no set-aside designation, this purchase order will be performed in Parker, Arizona, and represents one of five related contract actions awarded under...
- Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, was awarded a delivery order valued at $242,163.20 by the Indian Health Service (IHS) for Option Year Two of a contract covering laboratory supplies and testing services. The award, issued on July 2, 2024, covers the period from September 1, 2024, through August 31, 2025, with an ultimate completion date of August 31, 2028. The contract utilizes a firm fixed-price pricing model with no set-aside designation and is...
- The U.S. Indian Health Service (IHS) awarded a $115,600.00 firm fixed-price purchase order contract to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions, for the provision of CEPHEID TEST KITS. The contract has an ultimate completion date of July 10, 2025 and was awarded on January 30, 2024. Cepheid is a prime contractor that provides advanced diagnostic systems and test kits for infectious diseases, genetic conditions, and clinical testing to various federal agencies,...
- The U.S. Indian Health Service awarded a $168,475.00 firm fixed-price purchase order contract to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract is for the administrative modification to extend the period of performance to December 31, 2025. Cepheid provides comprehensive molecular diagnostic technologies to various federal agencies, including the Department of Veterans Affairs (VA), Indian Health Service (IHS), and Defense...
- This is a firm fixed-price delivery order contract awarded by the Indian Health Service (IHS), a civilian agency, to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions. The contract is valued at $176,833.92 and covers the period from July 1, 2025, to June 30, 2026. Cepheid will provide the IHS with its GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services for detecting infectious diseases such as COVID-19, influenza, and...
- This is a firm fixed-price delivery order contract awarded by the Indian Health Service (IHS), a civilian federal agency, to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions. The $173,496.00 contract is for the period of July 1, 2025 to June 30, 2026 and does not have a set-aside designation. Cepheid, the prime contractor, provides the IHS with GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services for detecting infectious...
- The U.S. Department of Health and Human Services' Indian Health Service (IHS) awarded a $23,213.50 firm fixed-price purchase order contract to Cepheid, a for-profit manufacturer of molecular diagnostic solutions, to provide lab supplies to the IHS facility in Sisseton, South Dakota. The contract has an ultimate completion date of April 28, 2025 and was awarded on February 26, 2025, with no set-aside designation. This award aligns with Cepheid's history of providing diagnostic testing...
- The Indian Health Service (IHS) awarded Modification No. P00007 to Cepheid to exercise Option Year Four of the Cepheid Advantage Services Agreement at AAIHS, covering the period December 1, 2025 through November 30, 2026. This firm fixed-price purchase order, valued at $871,183.98, represents a continuation of Cepheid's molecular diagnostic solution services at the Albuquerque, New Mexico location. The award carries no set-aside designation, and the original contract was initially awarded on...
- The Indian Health Service awarded a firm fixed-price purchase order to Cepheid Inc. for laboratory supplies and testing consumables on an as-needed basis, with an effective date of February 8, 2024, and ultimate completion date of December 31, 2025. The $1.49M contract covers supplies for the Cepheid GeneXpert analyzer system, including microbiology supplies, reagent kits, and COVID-19 test kits to be delivered to the Chinle, Arizona location. The contract has no set-aside designation and...
- The Indian Health Service awarded a $787,325 firm fixed price delivery order against its Agency-Wide Indefinite Delivery Indefinite Quantity contract with Cepheid for COVID-19 reagents and supplies. As part of the Department of Health and Human Services' efforts to address the Coronavirus pandemic, this order will provide Cepheid test kits and related materials to IHS through July 2021. Cepheid, a subsidiary of Danaher Corporation, will deliver the products from its Phoenix, Arizona location for...
The Indian Health Service (IHS) awarded a $45,900 firm fixed-price purchase order to Cepheid Inc. on December 1, 2025, for molecular diagnostic solutions with a completion date of November 30, 2030. The contract, which carries no set-aside designation, will be performed in Tohatchi, New Mexico. Cepheid, a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems and reagents, will deliver diagnostic testing capabilities to support IHS healthcare operations. The company specializes in GeneXpert diagnostic systems and associated test kits for detecting infectious diseases and other medical conditions, with a proven track record of providing similar solutions across multiple federal health agencies. This purchase order represents a continuation of Cepheid's existing relationship with federal healthcare systems. The company currently holds significant indefinite delivery vehicle contracts with the Department of Veterans Affairs, including a $32.8 million single-award IDV with Veterans Integrated Service Network 6 and a $2.5 million contract with Veterans Integrated Service Network 21, both providing molecular diagnostic testing reagents and assays for conditions including COVID-19, influenza, RSV, tuberculosis, and other infectious diseases. The IHS award demonstrates the company's competitive positioning in the federal molecular diagnostics market and aligns with the agency's mission to provide quality healthcare services to American Indian and Alaska Native populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.2k | 12/1/25 |